Thyroid Eye Disease is an autoimmune condition that inflames and damages the tissues around the eyes — most often in patients with Graves' disease. Early recognition and expert management can prevent vision loss.
Thyroid Eye Disease (TED), also called Graves' ophthalmopathy or Graves' orbitopathy, is an autoimmune disorder in which the immune system attacks the muscles and fatty tissue behind the eyes. It occurs most commonly in patients with Graves' disease but can also appear in those with Hashimoto's thyroiditis or even normal thyroid function. Dr. Guttler has managed TED patients for over 50 years and has appeared on NBC's Today Show to discuss this condition.
Patient Story
Margaret, 52
Margaret noticed her eyes looked different in photos — slightly bulging, with a persistent stare. Her optometrist thought it was dry eye. Six months later, she developed double vision and was referred to Dr. Guttler. Her TSH was suppressed and her TRAb antibodies were markedly elevated. Dr. Guttler coordinated care with an orbital specialist, started selenium supplementation during the active phase, and monitored her closely. Two years later, her eyes have stabilized and her vision is fully intact. 'I had no idea my thyroid was behind all of this,' she said.
TED is caused by TSH receptor antibodies (TRAb) that stimulate not only the thyroid gland but also receptors in the orbital tissues. This triggers inflammation, swelling of the eye muscles, and expansion of orbital fat — pushing the eyeball forward (proptosis). Smoking dramatically worsens TED and is the single most important modifiable risk factor.
Early symptoms include eye redness, irritation, excessive tearing, and a gritty sensation. As the disease progresses, patients may develop eyelid retraction (the classic 'stare'), proptosis (bulging eyes), double vision (diplopia), and in severe cases, optic nerve compression threatening vision. The active inflammatory phase typically lasts 12–18 months before stabilizing.
Diagnosis is based on clinical examination, TRAb antibody levels, and orbital imaging (CT or MRI). The Clinical Activity Score (CAS) helps determine whether the disease is in the active inflammatory phase — when anti-inflammatory treatment is most effective — or the stable fibrotic phase, when surgical rehabilitation is considered.
Mild TED is managed with lubricating eye drops, selenium supplementation (shown in European trials to slow progression), and smoking cessation. Moderate-to-severe active TED is treated with IV methylprednisolone pulse therapy. Teprotumumab (Tepezza), an IGF-1R inhibitor, is a breakthrough biologic approved in 2020 that dramatically reduces proptosis and diplopia. Orbital decompression surgery, strabismus surgery, and eyelid surgery are reserved for the stable phase.
Controlling thyroid function is essential but does not always control TED — the two conditions can run independent courses. Radioactive iodine (RAI) treatment for Graves' disease can worsen TED and should be preceded by corticosteroid prophylaxis in at-risk patients. Total thyroidectomy may be preferable to RAI in patients with active or moderate TED.
Dr. Guttler screens every Graves' disease patient for TED at diagnosis and at each follow-up visit. He measures TRAb levels, assesses the Clinical Activity Score, and coordinates care with ophthalmologists and orbital surgeons when needed. His goal is to catch TED early, protect vision, and guide patients through the active phase with the least possible disfigurement.
Thyroid Eye Disease (Graves' Ophthalmopathy)
Graves' disease can affect the eyes, causing bulging, double vision, and discomfort. Dr. Guttler explains the connection and treatment options.
Lecture 3: Hyperthyroidism & Graves' Disease
An overactive thyroid can cause heart palpitations, weight loss, and anxiety. Dr. Guttler explains Graves' disease, toxic nodules, and treatment choices.
Hyperthyroidism: When Your Thyroid Works Too Hard
Heart palpitations, weight loss, anxiety — an overactive thyroid produces a distinct set of symptoms. Learn how to recognize and treat hyperthyroidism.